Small Airway Involvement in Patients With Chronic Hypersensitivity Pneumonitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

27 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-09-01

Study Completion Date

2017-11-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hypersensitivity pneumonitis (HP) is a syndrome with variable clinical presentation in which lung inflammation is caused by inhalation of specific organic antigens or low molecular weight particles in previously sensitized individuals. Systemic symptoms may or may not be present. Chronic HP represents the final stage of the disease, caused by prolonged exposure to a particular antigen, leading to pulmonary fibrosis. In chronic HP, pulmonary function tests (PFTs) commonly present a restrictive ventilatory pattern, with decreased diffusion of carbon monoxide (DLCO). Some patients can also have obstructive disorders with expiratory flow limitation, due to obstruction of the small airways typically caused by bronchiolar involvement in this pathology. However, PFTs are relatively insensitive for detecting small airway involvement when there is concomitant interstitial fibrosis. First, conventional PFTs may be normal in patients with small airway involvement, since they contribute to less than 30% of the total airway resistance. In addition, damage to the small airways in HP is generally occurring parallel to areas of focal fibrosis - even when small airways are involved, these regions can be completely ignored, since they are excluded from ventilation. In summary, traditional PFTs are not sufficiently sensitive to detect diffuse small airway involvement in these diseases. In these cases, other functional tests, such as forced oscillation technique (FOT) and high resolution computer tomography (HRCT) scans of the chest with expired studies, could be used for this purpose.

This will be a cross-sectional study, which will include the following evaluations in 28 patients with HP recruited from our clinic:

\- Clinical variables: (A) demographic and anthropometric data; (B) Clinical data: Onset of symptoms and time of diagnosis

C) Dyspnea score:

D) Smoking: \* Current or former smoker \* Smoking history (number of cigarettes smoked per day and for how long);

* Spirometry with forced and slow maneuvers before and after bronchodilator (salbutamol);
* Plethysmography to measure lung volumes;
* Diffusion capacity of carbon monoxide (DLCO);
* High-resolution chest CT with expiratory scans;
* Six-minute walk test;
* Cardio-respiratory test using a maximal incremental treadmill.
* Forced oscillation technique (FOT).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety Study of 20,000 EU of Clinical Center Reference Endotoxin in Allergic Adults With and Without Mild Asthma

NCT00630461

Mild Allergic Rhinitis Mild Allergic Rhinitis With Mild Asthma

TERMINATED PHASE1

Airborne Ultrafine and Fine Particulate Matter: A Cause for Endothelial Dysfunction in Man?

NCT00814281

Airway Inflammation

COMPLETED NA

Pollutant Altered Allergic Responses

NCT00011440

Allergic Rhinitis Allergy

COMPLETED

Effects of 20,000 EU of Clinical Center Reference Endotoxin (CCRE) Versus Placebo(ENDOHEART)

NCT03623022

Healthy

COMPLETED PHASE1

Impact of Age on the Prevalence of Allergic Sensitization

NCT02730520

Allergy

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hypersensitivity pneumonitis (HP) is a syndrome with variable clinical presentation, in which inflammation in lung parenchyma is caused by inhalation of organic antigens or specific low molecular weight substances in previously sensitized individuals. Systemic symptoms may or not be present. Chronic HP represents the final stage of this disease, where prolonged exposure to a particular antigen would lead to lung fibrosis. The list of new antigens is growing, but the main antigens responsible for this disease are exposure to mold and birds.

Not all exposed individuals develop HP. The pathophysiology involves initial exposure and a subsequent decrease in antigen tolerance. Genetic susceptibility can also modulate the immune response to a specific antigen.

There are no reliable epidemiological data on the incidence or prevalence of HP. Differences in the type of antigen sensitization, lack of standardized diagnostic criteria and underreporting are possible factors. In Mexico, one of the few population surveys showed an estimated incidence of 30 cases per 100000 inhabitants in 2 years (1988-1990); however, there are some bias that limit the extrapolation of data to other contexts.

The patient rarely associates the onset of symptoms with a relevant exposure, making it important to actively search for environmental factors against respiratory complaints. It is believed that intermittent exposure to an antigen, long-term exposure to a small load of antigen or a cumulative effect of multiple episodes of acute exposure can cause chronic HP. It is noteworthy that only a small proportion of patients with a single episode of acute exposure will develop chronic HP.

In chronic HP, the patient complains of dyspnea on exertion and dry cough. Systemic symptoms such as fever and weight loss are rarely reported and may be associated with episodes of acute exposure. Physical examination reveals crackles and less commonly, digital clubbing. Auscultation may reveal the presence of squawks arising from the abrupt opening of small airways. Hypoxemia is found in patients with more severe lung disease.

The differential diagnosis with other fibrosing interstitial diseases is challenging, due to the overlap of clinical history, functional and tomographic findings in the terminal stages of these pathologies. There is no gold standard test for diagnosis of HP in all its forms: the diagnosis results in the combination of epidemiological, clinical, radiological data and other exams.

High resolution computer tomography (HRCT) has a fundamental role in the differential diagnosis. However, in advanced stages, the tomographic scans can demonstrate a pattern indistinguishable from nonspecific interstitial pneumonia (NSIP) or usual interstitial pneumonia (UIP), with presence of architectural distortion, traction bronchiectasis and bronchiolectasis, minimum ground glass opacities and honeycombing. The interpretation of HRCT allows "clues" for the differential diagnosis with other idiopathic intersticial pneumonias (IIPs). In comparative HRCT studies, there were some findings showing small airway involvement, such as lobular areas with decreased attenuation and vascularity, air trapping and ground glass or centrilobular micronodules Surgical biopsy may aid in the differential diagnosis of HP from other chronic idiopathic interstitial pneumonitis, especially when exposure is unclear. Even in advanced fibrosis, the accentuation of inflammation around the small airways is the major finding.

Pulmonary function tests (PFTs) commonly show restrictive ventilatory defect with decreased DLCO. There may be concomitant obstructive ventilatory defect, secondary to involvement of the small airways.

However, PFTs are relatively insensitive for detecting small airway involvement when there is concomitant interstitial fibrosis. Firstly, conventional PFTs may be normal in patients with involvement of small airways since they contribute to less than 30% of total airway resistance. Furthermore, damage to small airways in HP is generally focal occurring in parallel with fibrosed areas - even when small airways are involved, these regions may be completely disregarded since they are excluded from ventilation, with PFTs globally featuring a standard restrictive pattern.

In summary, traditional PFTs are not sensitive enough to detect diffuse small airway involvement in these diseases, no matter how severe it is, neither can detect focal changes. In these cases, the investigators hypothesize that other tests, such as forced oscillometry technique (FOT), with its experience widely recognized in the context of evaluation of obstructive diseases like asthma and chronic obstructive pulmonary disease (COPD) and the technique of negative expiratory pressure (NEP) could be used for this purpose. For now, imaging tests, especially high-resolution tomography with expiratory scans, seem to be more sensitive to detect small airway involvement.

Removal of the causal exposure is the treatment of choice. The use of corticosteroids reduces the duration of the acute phase, but does not affect long-term prognosis. Inhaled corticosteroids and bronchodilators may be used when there is evidence of airflow limitation, but there is no evidence basing its use.

2\. Study hypothesis

The investigators' hypothesis is that a proportion of patients diagnosed with chronic HP exhibit expiratory flow limitation, due to airway obstruction caused mostly by the bronchiolar involvement characteristic of this pathology. This involvement could be quantified through other functional tests, such as FOT, and imaging techniques such as high resolution CT scan of the chest with expiratory scans. This may be one of the mechanisms that justifies the lower exercise capacity and greater degree of dyspnea on exertion in these individuals, together with other factors secondary to interstitial lung fibrosis, even in those patients with normal FEV1 (forced expiratory volume in 1 second) /FVC (forced vital capacity) , FEV1, residual volume (RV) and resistance.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypersensitivity Pneumonitis Airway Disease Small

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Chronic HP patients

Chronic hypersensitivity pneumonitis patients - use of salbutamol

Group Type OTHER

Salbutamol

Intervention Type DRUG

Salbutamol after spirometry, plethysmography and forced oscillation technique.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Salbutamol

Salbutamol after spirometry, plethysmography and forced oscillation technique.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Aerolin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of chronic hypersensitivity pneumonitis confirmed by:

* patients with known exposure to antigen, tomographic criteria and absence of other diagnoses;
* confirmation with histology obtained by transthoracic biopsy, surgical biopsy or bronchoalveolar lavage with lymphocytosis above 30%;
* Age between 18 to 75 years;
* Clinically stable (no exacerbations or hospitalizations related to the underlying disease) for at least 6 weeks;
* Compliance with signing an informed consent for participation in the project.

Exclusion Criteria

* Patients with FEV1 and / or DLCO \<30% predicted;
* Patients using supplemental oxygen;
* Previous diagnosis of asthma or COPD;
* Pregnant women;
* Musculoskeletal disorders that limit exercise;
* Another medical condition that might interfere with the execution of tests;
* Current or past smoking history with tobacco intake greater than 30 pack-years;
* Severe heart disease functional class New York Heart Association (NYHA) III-IV) and / or decompensated hear failure.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No